Says R&D "remains number one priority." Says capital allocation strategy "clear and remains unchanged." Says "confident" in achieving 2025 Pharmaceutical business sales targets. Expects "above market growth" in Pharmaceutical in 2023. Says "pleased" with integration of Abiomed. Comments taken from Q1 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ:
- Johnson & Johnson Earnings Report: Is it a Beat?
- JNJ Up as Q1 Results Beat Estimates, Raises Outlook
- Johnson & Johnson raises quarterly dividend 5.3% to $1.19 from $1.13 per share
- Genmab announces Q1 net sales of DARZALEX $2.26B
- Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65